Changing Therapeutic Regimens in Benign Prostatic Hyperplasia: Clinical and Economic Considerations

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.19, Iss.2, 2001-01, pp. : 131-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Doxazosin Gastrointestinal Therapeutic System: A Review of its Use in Benign Prostatic Hyperplasia

By Goldsmith David R. Plosker Greg L.

Drugs, Vol. 65, Iss. 14, 2005-01 ,pp. : 2037-2047

Adis International

Access to resources Recommend Favorite

Treatment options for benign prostatic hyperplasia

By Thurlow R.J.

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 225-246

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride for the treatment of benign prostatic hyperplasia

By Wu Christopher Kapoor Anil

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1399-1408

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride/Tamsulosin: In Benign Prostatic Hyperplasia

By Keating Gillian M.

Drugs & Aging, Vol. 29, Iss. 5, 2012-05 ,pp. : 405-419

Adis International

Access to resources Recommend Favorite

Alfuzosin: A Review of the Therapeutic Use of the Prolonged-Release Formulation Given Once Daily in the Management of Benign Prostatic Hyperplasia

By McKeage K. Plosker G.L.

Drugs, Vol. 62, Iss. 4, 2002-04 ,pp. : 633-653

Adis International

Access to resources Recommend Favorite